|
NICE Turnaround On Novartis' Xolair To Be Discussed At Asthma & Copd …
Big News Network.com asthma in adults, adolescents and children. The decision comes as a result of a move by Novartis to offer a patient access scheme to discount Xolair's list price. An estimated 65 million people currently suffer from COPD globally with 300 million … |
View full post on asthma – Google News